US NIH to fund Proximagen's Phase II naluzotan trial
This article was originally published in Scrip
Executive Summary
Proximagen, the UK biotech focused on central nervous system (CNS) disorders, has signed a research and development agreement with the US National Institute of Neurological Disorders and Stroke (NINDS).